Skip to main content
. 2020 Dec 1;8(4):716. doi: 10.3390/vaccines8040716

Figure 1.

Figure 1

The characterization of recombinant live attenuated influenza vaccine (LAIV)-G1 and LAIV-G2 viruses. (A) Schematic representation of LAIV and recombinant LAIV expressing respiratory syncytial virus (RSV) G conserved glycoprotein aa131–130 domain with amino acid sequence indicated using different linkers. (B) RSV G specific mAb 131-2G reactivity of LAIV, LAIV-G1, and LAIV-G2 viruses. (C) Anti-A/PR8 serum reactivity of LAIV, LAIV-G1, and LAIV-G2 viruses. FI-RSV: formalin-inactivated RSV, LAIV: A/PR8 LAIV, including ts phenotypic mutations in PB1 and PB2 genes, LAIV-G1: rA/PR8 LAIV-G1 expressing HA-G protein using a linker (GGGGS) between RSV G and HA N-terminal ectodomain, LAIV-G2: rA/PR8 LAIV-G2 expressing HA-G protein using a linker (AAAPGAA) at both G-HA conjugated sites. (D) Western blotting of LAIV, LAIV-G1, and LAIV-G2 using mAb 131-2G. 1: Marker, 2: LAIV-G1 (10 µg), 3: LAIV-G2 (10 µg), 4: RSV G-protein (10 µg), and 5: LAIV (10 µg). The arrow indicates chimeric G-HA proteins.